FOLH1 and neoplasm: showed—in an intrapatient comparative dosimetry study of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in 4 patients with mCRPC—that 177Lu-rhPSMA-10.1 has a significantly increased tumor-absorbed dose, resulting in an improved tumor-to-kidney therapeutic index compared with 177Lu-PSMA-I&T (26).